Prediction of metabolism-induced hepatotoxicity on three-dimensional hepatic cell culture and enzyme microarrays
- 483 Downloads
Human liver contains various oxidative and conjugative enzymes that can convert nontoxic parent compounds to toxic metabolites or, conversely, toxic parent compounds to nontoxic metabolites. Unlike primary hepatocytes, which contain myriad drug-metabolizing enzymes (DMEs), but are difficult to culture and maintain physiological levels of DMEs, immortalized hepatic cell lines used in predictive toxicity assays are easy to culture, but lack the ability to metabolize compounds. To address this limitation and predict metabolism-induced hepatotoxicity in high-throughput, we developed an advanced miniaturized three-dimensional (3D) cell culture array (DataChip 2.0) and an advanced metabolizing enzyme microarray (MetaChip 2.0). The DataChip is a functionalized micropillar chip that supports the Hep3B human hepatoma cell line in a 3D microarray format. The MetaChip is a microwell chip containing immobilized DMEs found in the human liver. As a proof of concept for generating compound metabolites in situ on the chip and rapidly assessing their toxicity, 22 model compounds were dispensed into the MetaChip and sandwiched with the DataChip. The IC50 values obtained from the chip platform were correlated with rat LD50 values, human C max values, and drug-induced liver injury categories to predict adverse drug reactions in vivo. As a result, the platform had 100% sensitivity, 86% specificity, and 93% overall predictivity at optimum cutoffs of IC50 and C max values. Therefore, the DataChip/MetaChip platform could be used as a high-throughput, early stage, microscale alternative to conventional in vitro multi-well plate platforms and provide a rapid and inexpensive assessment of metabolism-induced toxicity at early phases of drug development.
KeywordsMetabolism-induced hepatotoxicity Three-dimensional (3D) cell culture array Metabolizing enzyme microarray DataChip/MetaChip High-throughput toxicity screening
We acknowledge support from the National Institute of Environmental Health Sciences (ES018022, ES012619, and ES025779) and National Science Foundation (IIP-0740592). This work was partly supported by Samsung Electro-Mechanics Co. (SEMCO), Ltd. The authors are grateful to Dr. Byeong-Cheon Koh (former Executive Vice President) and members of the cell chip research group in SEMCO for helpful suggestions and assistance with chip fabrication.
Compliance with ethical standards
Conflict of interest
The research was partly supported by Samsung Electro-Mechanics Co. (SEMCO). Thus, the authors declare that there might be potential conflict of interest.
- Andersson DA, Gentry C, Alenmyr L, Killander D, Lewis SE, Andersson A, Bucher B, Galzi JL, Sterner O, Bevan S, Högestätt ED, Zygmunt PM (2011) TRPA1 mediates spinal antinociception induced by acetaminophen and the cannabinoid ∆(9)-tetrahydrocannabiorcol. Nat Commun 22(2):551. https://doi.org/10.1038/ncomms1559 CrossRefGoogle Scholar
- Astrid S, Helmut S, Roland S (2007) Drug metabolism as catalyzed by human cytochrome P450 systems. In: Metal ions in life science. Volume 3: the ubiquitous roles of cytochrome P450 proteins. Wiley Online Library, EnglandGoogle Scholar
- Combes R, Balls M, Bansil L, Barratt M, Bell D, Botham P, Broadhead C, Clothier R, George E, Fentem J, Jackson M, Indans I, Loizou G, Navaratnam V, Pentreath V, Phillips B, Stemplewski H, Stewart J (2002) An assessment of progress in the use of alternatives in toxicity testing since the publication of the report of the second FRAME Toxicity Committee (1991). Altern Lab Anim 30:365–406PubMedGoogle Scholar
- Costas I (2008) Cytochromes P450: role in the metabolism and toxicity of drugs and other xenobiotics. Royal Society of Chemistry, CambridgeGoogle Scholar
- DiMasi JA, Grabowski HG (2012) R&D costs and returns to new drug development: a review of the evidence. Oxford University Press, Oxford, pp 21–46Google Scholar
- Gustafsson F, Foster AJ, Sarda S, Bridgland-Taylor MH, Kenna JG (2014) A correlation between the in vitro drug toxicity of drugs to cell lines that express human P450s and their propensity to cause liver injury in humans. Toxicol Sci 137:189–211. https://doi.org/10.1093/toxsci/kft223 CrossRefPubMedGoogle Scholar
- Hewitt NJ, Lechón MJ, Houston JB, Hallifax D, Brown HS, Maurel P, Kenna JG, Gustavsson L, Lohmann C, Skonberg C, Guillouzo A, Tuschl G, Li AP, LeCluyse E, Groothuis GM, Hengstler JG (2007) Primary hepatocytes: current understanding of the regulation of metabolic enzymes and transporter proteins, and pharmaceutical practice for the use of hepatocytes in metabolism, enzyme induction, transporter, clearance, and hepatotoxicity studies. Drug Metab Rev 39:159–234. https://doi.org/10.1080/03602530601093489 CrossRefPubMedGoogle Scholar
- Huch M, Gehart H, van Boxtel R, Hamer K, Blokzijl F, Verstegen MM, Ellis E, van Wenum M, Fuchs SA, de Ligt J, van de Wetering M, Sasaki N, Boers SJ, Kemperman H, de Jonge J, Ijzermans JN, Nieuwenhuis EE, Hoekstra R, Strom S, Vries RR, van der Laan LJ, Cuppen E, Clevers H (2015) Long-term culture of genome-stable bipotent stem cells from adult human liver. Cell 160:299–312. https://doi.org/10.1016/j.cell.2014.11.050 CrossRefPubMedPubMedCentralGoogle Scholar
- Mahayni H, Rekhi GS, Uppoor RS, Marroum P, Hussain AS, Augsburger LL, Eddington ND (2000) Evaluation of external predictability of an in vitro–in vivo correlation for an extended-release formulation containing metoprolol tartrate. J Pharm Sci 89:1354–1361. https://doi.org/10.1002/1520-6017(200010)89:10<1354::AID-JPS13>3.0.CO;2-P CrossRefPubMedGoogle Scholar
- OECD (2002) Guidelines for the testing of chemicals/OECD series on testing and assessment harmonised integrated classification system for human health and environmental hazards of chemical substances and mixtures. OECDGoogle Scholar
- Sivaraman A, Leach JK, Townsend S, Iida T, Hogan BJ, Stolz DB, Fry R, Samson LD, Tannenbaum SR, Griffith LG (2005) A microscale in vitro physiological model of the liver: predictive screens for drug metabolism and enzyme induction. Curr Drug Metab 6:569–591. https://doi.org/10.2174/138920005774832632 CrossRefPubMedGoogle Scholar
- Watanabe T, Shibata N, Westerman KA, Okitsu T, Allain JE, Sakaguchi M, Totsugawa T, Maruyama M, Matsumura T, Noguchi H, Yamamoto S, Hikida M, Ohmori A, Reth M, Weber A, Tanaka N, Leboulch P, Kobayashi N (2003) Establishment of immortalized human hepatic stellate scavenger cells to develop bioartificial livers. Transplantation 75(11):1873–1880. https://doi.org/10.1097/01.TP.0000064621.50907.A6 CrossRefPubMedGoogle Scholar
- Westra IM, Mutsaers HA, Luangmonkong T, Hadi M, Oosterhuis D, de Jong KP, Groothuis GM, Olinga P (2016) Human precision-cut liver slices as a model to test antifibrotic drugs in the early onset of liver fibrosis. Toxicol In Vitro 35:77–85. https://doi.org/10.1016/j.tiv.2016.05.012 CrossRefPubMedGoogle Scholar